The company said the newly cleared test complements its i-STAT TBI plasma test. Tools that can aid in the evaluation of concussion can get people the required answers and treatment, Abbott explained. Misdiagnosis or lack of diagnosis only exacerbates these effects. Those who sustain TBI are more likely to have another one, Abbott said. These effects can last anywhere a few days post-injury but they can also prove permanent.
TBIs, caused by a bump, blow or whiplash to the head, can lead to the risk of short- and long-term effects. That’s great news for both doctors and people who are trying to find out if they have suffered a traumatic brain injury.” Abbott and the need to test for TBI efficiently “Now that this test will be widely available in labs across the country, medical centers will be able to offer an objective blood test than can aid in concussion assessment. Beth McQuiston, M.D., medical director in Abbott’s diagnostics business. Others wonder if a visit to the doctor or emergency room for a possible concussion will provide them with meaningful answers or care,” said Dr. “People sometimes minimize a hit to the head, thinking it’s no big deal. In elevated concentrations, these biomarkers closely correlate to brain injury. The company designed the test to measure two biomarkers in the blood. For those with negative results, it rules out the need for a CT scan and can eliminate hospital wait time. This helps clinicians quickly assess concussion and triage patients. It provides clinicians with an objective way to quickly assess mild TBIs, otherwise known as concussions.Ībbott said in a news release that its Alinity i TBI lab test offers a new reliable result in 18 minutes. hospitals, runs on the Abbott Alinity i laboratory instrument. Abbott (NYSE:ABT) announced that it received FDA clearance for the first commercially available laboratory traumatic brain injury (TBI) blood test.
0 kommentar(er)
